AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation to import Durvalumab for sale and distribution. The drug, combined with chemotherapy, treats resectable non-small cell lung cancer without specific genetic mutations. Lung cancer remains a significant cause of mortality in India, highlighting the importance of this development.